unknown
Stage
1
Investors
About
Entrada Therapeutics develops intracellular therapeutics using its proprietary Endosomal Escape Vehicle (EEV) platform to deliver a variety of therapeutic molecules, including RNA, antibodies, and enzymes, aiming to treat serious diseases such as Duchenne Muscular Dystrophy.
Explore Entrada Therapeutics, Inc.'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.